By George Ongkojoyo 
In a significant breakthrough for global infectious disease research, investigators at Johns Hopkins Medicine have identified an experimental cancer drug that may drastically improve the efficacy of standard tuberculosis (TB) treatments. The study, published on March 27 in the journal Nature Communications, suggests that by modulating the way infected cells die, the drug navitoclax can reduce lung damage, accelerate the clearance of bacteria, and potentially shorten the arduous treatment regimens currently required to combat the disease. This research, conducted using mouse models and supported by the National Institutes of Health (NIH), highlights a shift toward host-directed therapies that focus on the patient’s biological response rather than solely attacking the pathogen itself.
The Global Resurgence and Persistent Challenge of Tuberculosis
Tuberculosis remains one of the most formidable public health challenges of the 21st century. Despite being both preventable and treatable, the World Health Organization (WHO) recently reported that TB has likely reclaimed its position as the leading cause of death from a single infectious agent globally. In 2023 alone, an estimated 10.8 million people contracted the disease, and approximately 1.25 million people succumbed to it.
The current standard of care for TB involves a grueling six-month course of multiple antibiotics, commonly referred to as the RHZ regimen (rifampin, isoniazid, and pyrazinamide). For many patients, especially those in low-resource settings, adhering to this long-term protocol is difficult, leading to high rates of treatment default. This non-compliance contributes to the rise of multi-drug-resistant TB (MDR-TB), which is significantly harder and more expensive to treat. Furthermore, even those who are successfully "cured" of the infection often suffer from post-TB lung disease—a condition characterized by chronic lung dysfunction, scarring (fibrosis), and reduced quality of life that affects tens of millions of survivors worldwide.
A New Strategy: Host-Directed Therapy
The research led by Sanjay Jain, M.D., a pediatric infectious diseases specialist at Johns Hopkins Children’s Center, introduces a "host-directed" approach. Traditional TB treatments focus exclusively on killing Mycobacterium tuberculosis, the bacterium responsible for the disease. However, the Johns Hopkins team explored how the body’s own cells respond to the infection and how that response can be manipulated to improve outcomes.
"Current treatment regimens for TB are lengthy, expensive and leave patients vulnerable to relapse and lung scarring," says Dr. Jain. "Our research shows that adding in a host-directed therapy has extraordinary promise to solve these problems."
The study focused on Bcl-2, a family of anti-apoptotic proteins. In a healthy immune response, cells infected with bacteria undergo apoptosis—a form of programmed, "gentle" cell death that contains the pathogen and prevents it from spreading. However, Mycobacterium tuberculosis has evolved a mechanism to hijack the host’s molecular pathways, forcing the cells to produce Bcl-2. This prevents apoptosis and instead triggers necrosis—a "messy" and uncontrolled form of cell death.
Dr. Jain uses a vivid analogy to describe the difference: "While apoptosis could be compared to controlled demolition of a building, necrosis is more like destruction by a bomb." Necrosis leads to widespread inflammation, the formation of large lesions, and permanent tissue damage, which allows the bacteria to multiply and hide from the immune system.
Experimental Methodology and the Role of Navitoclax
To test whether they could flip the switch back from necrosis to apoptosis, the researchers utilized navitoclax. Navitoclax is an experimental Bcl-2 inhibitor currently undergoing clinical trials as a cancer treatment, designed to force malignant cells into programmed cell death.
In the study, mice exposed to Mycobacterium tuberculosis were divided into groups. One group received the standard RHZ antibiotic treatment, while the other received RHZ plus navitoclax. To monitor the progress of the infection and the physical state of the lungs in real-time, the team employed clinically translatable positron emission tomography (PET) imaging. This advanced technology allowed researchers to visualize apoptosis and fibrosis (scarring) within the living animals, providing a window into how the host-directed therapy was altering the course of the disease.
Significant Findings: 40% Reduction in Lung Damage
The results of the four-week trial were striking. The mice that received the combination therapy of antibiotics and navitoclax showed significant improvements over those receiving antibiotics alone:
- Reduced Lesions: Mice treated with navitoclax saw a 40% reduction in necrotic lesions in their lungs.
- Increased Apoptosis: PET imaging revealed that the addition of the cancer drug doubled the amount of pulmonary apoptosis, suggesting the body was successfully using "controlled demolition" to manage infected cells.
- Decreased Scarring: Lung scarring, or fibrosis, was reduced by 40%. This is a critical finding for the prevention of post-TB lung disease.
- Enhanced Bacterial Clearance: Although navitoclax does not kill bacteria directly, the environment it created allowed the antibiotics to work more efficiently. The bacterial burden in the lungs was decreased 16 times more effectively in the combination group compared to the standard treatment group.
- Limited Spread: The infection was significantly less likely to spread from the lungs to other vital organs, such as the spleen.
Medha Singh, Ph.D., the study’s first author and a pediatric infectious diseases fellow at the Johns Hopkins University School of Medicine, noted that while previous research had suggested Bcl-2 inhibition as a potential strategy, this was the first time it was tested alongside a real-world antibiotic regimen. The synergy between the drug and the standard antibiotics suggests that the host-directed therapy could act as a potent "force multiplier."
Addressing Post-TB Lung Disease and Long-Term Outcomes
The implications of this study extend far beyond the initial treatment phase. One of the most overlooked aspects of the TB crisis is the long-term morbidity associated with the disease. Tens of millions of people live with permanent lung impairment because of the necrosis and scarring caused during the infection.
By reducing the severity of necrosis and promoting a more regulated cell death process, navitoclax could potentially ensure that TB survivors regain full lung function. This would alleviate the long-term economic and healthcare burdens associated with chronic respiratory issues in high-burden TB countries.
Laurence Carroll, Ph.D., an assistant professor of radiology and study author, emphasized the importance of the imaging techniques used. The ability to visualize lung scarring and early readouts of therapy success through PET scans could be a game-changer for future clinical trials in humans.
Broader Applications in Infectious Disease
The research team believes that the benefits of navitoclax and similar Bcl-2 inhibitors may not be limited to tuberculosis. Dr. Jain suggested that these findings could apply to other chronic bacterial infections that cause significant tissue damage, such as Staphylococcus aureus (Staph) and various non-tuberculosis mycobacteria, which are increasingly prevalent in the United States and elsewhere.
If the success seen in mouse models can be replicated in humans, it could lead to a paradigm shift in how we treat complex bacterial infections. Instead of simply increasing the dosage or duration of antibiotics—which fuels antibiotic resistance—doctors could use host-directed therapies to help the body’s own defenses finish the job more cleanly.
Path to Clinical Implementation
The next step for this research is the transition to human clinical trials. Because navitoclax is already being studied in the context of oncology, there is an existing body of data regarding its safety and dosage in humans. This could potentially accelerate the regulatory timeline for its use in TB treatment.
However, challenges remain. Clinical trials will need to determine the optimal timing for adding navitoclax to the antibiotic regimen and ensure that there are no adverse interactions in patients with varying degrees of illness. Dr. Jain expressed hope that the PET imaging approaches developed at the Johns Hopkins Center for Infection and Inflammation Imaging Research will play a central role in these trials, providing researchers with immediate feedback on how well the drug is preventing lung damage.
If successful, the integration of Bcl-2 inhibitors into standard TB protocols could shorten the current six-month treatment course to four months or less, significantly improving patient compliance and reducing the likelihood of relapse.
Conclusion: A New Horizon for TB Survivors
The Johns Hopkins study represents a vital step forward in the fight against a disease that has plagued humanity for millennia. By leveraging the tools of cancer research to fight infectious disease, the investigators have opened a new door for millions of patients.
As the global health community works toward the WHO’s "End TB Strategy" goals for 2030, innovations like navitoclax offer a glimmer of hope. The focus is no longer just on survival, but on ensuring that survivors can lead healthy, productive lives free from the debilitating effects of lung scarring. The transition from "bomb-like" necrosis to "controlled" apoptosis could be the key to finally turning the tide against tuberculosis.
Funding and Disclosures:
This study was supported by multiple grants from the National Institutes of Health (R01-AI153349, R01-AI145435-A1, R56-AI179012-A1, R01-AI190038, and S10-OD030381-A1). The authors, including Sanjay Jain, Medha Singh, and Laurence Carroll, declared no conflicts of interest under the policies of the Johns Hopkins University School of Medicine. Additional contributors from Johns Hopkins included Mona Sarhan, Nerketa Damiba, Alok Singh, and others from the departments of pediatrics and radiology.
